Publikationen, an denen er mitarbeitet Pilar Vizcarra (15)

2024

  1. Proteomic snapshot of saliva samples predicts new pathways implicated in SARS-CoV-2 pathogenesis

    Clinical Proteomics, Vol. 21, Núm. 1

2023

  1. A Risk Assessment Tool for Predicting Fragility Fractures in People with HIV: Derivation and Internal Validation of the FRESIA Model

    Journal of Bone and Mineral Research, Vol. 38, Núm. 10, pp. 1443-1452

  2. Author Correction: Differential abundance of lipids and metabolites related to SARS-CoV-2 infection and susceptibility (Scientific Reports, (2023), 13, 1, (15124), 10.1038/s41598-023-40999-5)

    Scientific Reports

  3. Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence of Clostridioides difficile infection: a propensity score analysis

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 3, pp. 823-827

  4. Differential abundance of lipids and metabolites related to SARS-CoV-2 infection and susceptibility

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Carbapenemase-producing Enterobacterales infections in COVID-19 patients

    Infectious Diseases, Vol. 54, Núm. 1, pp. 36-45

  2. Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2

    Journal of Infection, Vol. 85, Núm. 1, pp. 86-89

  3. Metabolic Snapshot of Plasma Samples Reveals New Pathways Implicated in SARS-CoV-2 Pathogenesis

    Journal of Proteome Research, Vol. 21, Núm. 3, pp. 623-634

2021

  1. COVID-19 and geographical area of origin

    Clinical Microbiology and Infection, Vol. 27, Núm. 4, pp. 632.e1-632.e5

  2. Implementation of a lung cancer screening initiative in HIV-infected subjects

    PLoS ONE, Vol. 16, Núm. 12 December

  3. Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers

    Emerging Microbes and Infections

  4. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

2020

  1. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort

    The Lancet HIV, Vol. 7, Núm. 8, pp. e554-e564

2019

  1. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting

    HIV Research and Clinical Practice, Vol. 20, Núm. 2, pp. 64-72

  2. Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine

    HIV Medicine, Vol. 20, Núm. 10, pp. 648-656